Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of AMG 416 for secondary hyperparathyroidism in hemodialysis patients
2012-002808-41Phase 3Completed
- Sponsor
- KAI Pharmaceuticals
- Start
- Nov 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of etelcalcetide in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), sponsored by KAI Pharmaceuticals. Started Nov 2012; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-002808-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002808-41.